EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PSMA‐Targeting Macrophage Membrane‐Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer

Keying Zhang, Bo Gao, Jingwei Wang, Yu Li, Chao Xu, Fa Yang, Shaojie Liu, Hongji Li, Chao Zhang, Xiangliang Meng, Zhaokun Shi, Rui Zhang iD und 8 weitere

Exploration · 2026-04 · 6 (2)

DOI: 10.1002/exp.20240393 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploration, online erschienen am 22.02.2026. Verfasst von Keying Zhang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Xijing Hospital Fourth Military Medical University Xi'an China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) is the most frequently diagnosed cancer in males. Advanced PCa is invasive and may spread rapidly. Current strategies could not fulfill the requirement for clinical application; thus, novel therapeutic strategies are still urgently needed. Nanoparticles are a promising strategy for targeted drug delivery and cancer treatment; however, the strong exogeneity and weak targeting limit their further application. Here, we developed a novel macrophage membrane‐coated nanoparticle that has transmembrane‐expressed gy‐1, a single‐chain antibody fragment (scFv) against prostate‐specific membrane antigen (PSMA), to endow the immune evasion and targeting property, which we named P‐MMCNPs. The Fe 3 O 4 @Au nanoparticles were used as the core of P‐MMCNPs, which confer P‐MMCNPs with the properties of multimodal imaging and photothermal therapy (PTT). Anti‐tumor cytotoxic drug maytansine (DM1) was loaded into the nanoparticles to obtain cytotoxicity. P‐MMCNPs were shown to have immune evasion capacity and prolonged circulation time and can be specifically distributed in PSMA‐positive tumors, thus enabling targeted imaging and targeted drug delivery. The macrophage membrane‐coated nanoparticles combined to inhibit tumor growth in vivo when loaded with DM1 and treated with PTT. Additionally, we found that P‐MMCNPs alone could inhibit tumor growth, which may be caused by cytokine neutralization by the macrophage membrane. Our work demonstrates that the innovative P‐MMCNPs serve as a versatile platform. This platform improves PCa‐targeted diagnostic and therapeutic efficacy while avoiding side effects. Moreover, it holds promise for expanding into the diagnosis and treatment of other diseases, with potential for clinical translation. Additionally, it offers novel insights into nanomedicine‐based combination therapy.

Schlagwörter

Stichwörter der Autor:innen

combined treatmentimmunomodulationmacrophage membrane‐coated nanoparticleprostate cancerprostate‐specific membrane antigentargeted multimodal imaging

Autor:innen und Institutionen

  • Department of Urology Xijing Hospital Fourth Military Medical University Xi'an China.
  • Institute of Orthopaedic Surgery Xijing Hospital Fourth Military Medical University Xi'an China.
  • The First Affiliated Hospital Southern University of Science and Technology Shenzhen China.
  • Department of Urology Daping Hospital Army Medical University Chongqing China.
  • State Key Laboratory of Cancer Biology Department of Immunology Fourth Military Medical University Xi'an China.
  • Engineering Research Center of Molecular & Neuroimaging Ministry of Education School of Life Science and Technology Xidian University Xi'an China.

ORCID-Profile: Rui Zhang, Weijun Qin

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities
  • China Postdoctoral Science Foundation

Zitieren

APA

Zhang, K., Gao, B., Wang, J., Li, Y., Xu, C., Yang, F., Liu, S., Li, H., Zhang, C., Meng, X., Shi, Z., Zhang, R., Zhang, R., Wang, Z., Wen, W., Zhang, Q., Zou, Y., Han, D., Bian, H., & Qin, W. (2026). PSMA‐Targeting Macrophage Membrane‐Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer. Exploration, 6(2). https://doi.org/10.1002/exp.20240393

Vancouver

Zhang K, Gao B, Wang J, Li Y, Xu C, Yang F, et al. PSMA‐Targeting Macrophage Membrane‐Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer. Exploration. 2026;6(2). doi:10.1002/exp.20240393

BibTeX
@article{Zhang2026,
  author = {Zhang, Keying and Gao, Bo and Wang, Jingwei and Li, Yu and Xu, Chao and Yang, Fa and Liu, Shaojie and Li, Hongji and Zhang, Chao and Meng, Xiangliang and Shi, Zhaokun and Zhang, Rui and Zhang, Ruili and Wang, Zhongliang and Wen, Weihong and Zhang, Qiang and Zou, Yuankang and Han, Donghui and Bian, Huijie and Qin, Weijun},
  title = {PSMA‐Targeting Macrophage Membrane‐Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer},
  journal = {Exploration},
  year = {2026},
  volume = {6},
  number = {2},
  doi = {10.1002/exp.20240393}
}
Kostenlos starten →